Hyperhomocystinemia in children with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 37, Issue 5, 2003, Pages 586-590

  Nakano, Emi ^a   Taylor, Christopher J ^a   Chada, Lavleen ^b   McGaw, Jean ^a   Powers, Hilary J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Folate; Homocysteine; Inflammatory bowel disease

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; VON WILLEBRAND FACTOR; 5-METHYLTETRAHYDROFOLATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); TETRAHYDROFOLIC ACID DERIVATIVE;

ADOLESCENT; AGE; ARTICLE; BLOOD LEVEL; BLOOD VESSEL INJURY; CHILD; CLINICAL ARTICLE; CROHN DISEASE; DIET; DISEASE ASSOCIATION; DISEASE MARKER; ENTERITIS; ERYTHROCYTE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; ULCERATIVE COLITIS; VASCULAR DISEASE; AGING; BLOOD; CROSS-SECTIONAL STUDY; GENETICS; PRESCHOOL CHILD; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; AGING; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INFLAMMATORY BOWEL DISEASES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TETRAHYDROFOLATES; THROMBOEMBOLISM; VITAMIN B 12; VON WILLEBRAND FACTOR;

EID: 1542389410     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200311000-00016     Document Type: Article

References (33)

1. Sawczenko A, Sandhu BK, Logan RF, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357:1093-4.
2. Korelitz BI. General observations on inflammatory bowel disease. In: Korelitz BI, Sohn N, eds. Inflammatory Bowel Disease: Experience and Controversy. Orlando, FL: Grune & Stratton Inc; 1985:3-29.
3. Walker-Smith JA, Macdonald TT. Clinical and diagnostic features of Crohn's disease and ulcerative colitis in childhood. In: eds. Chronic Inflammatory Bowel Disease in Childhood. London: Baillère Tindall; 1994:65-81.
4. Sandler RS, Eisen GM. Epidemiology of inflammatory bowel disease inflammation. In: Kirsner JB, eds. Inflammatory Bowel Disease. Philadelphia: WB Saunders; 2000:89-112.
5. Cosgrove M, Al-Atia RF, Jenkins HR. The epidemiology of paediatric inflammatory bowel disease. Arch Dis Child 1996;74: 460-1.
6. Koenigs KP, McPhedran P, Spiro HM. Thrombosis in inflammatory bowel disease. J Clin Gastroenterol 1987;9:627-31.
7. Graef V, Baggenstoss AH, Sauer WG, et al. Venous thrombosis occurring in nonspecific ulcerative colitis. Arch Intern Med 1966; 117:377-82.
8. Talbot RW, Heppell J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-5.
9. Cattaneo M, Vecchi M, Zighetti ML, et al. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 1998;80:542-5.
10. Mahmud N, Molloy A, McPartlin J, et al. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999;45:389-94.
11. Chowers Y, Sela BA, Holland R, et al. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol 2000;95:3498-502.
12. Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, et al. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig Dis Sci 2000;45:2347-51.
13. Romagnuolo J, Fedorak RN, Dias VC, et al. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001;96:2143-9.
14. Papa A, De Stefano V, Danese S, et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:2677-82.
15. Hoffbrand AV, Stewart JS, Booth CC, et al. Folate deficiency in Crohn's disease: incidence, pathogenesis, and treatment. Br Med J 1968;2:71-5.
16. Ubbink JB, Vermaak WJ, van der Merwe A, et al. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
17. Oldenburg B, Fijnheer R, van der Griend R, et al. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 2000;95:2825-30.
18. Eikelboom JW, Lonn E, Genest J Jr., et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
19. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-7.
20. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332:635-41.
21. Constans J, Blann AD, Resplandy F, et al. Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biologic markers of endothelial dysfunction. Br J Haematol 1999;107:776-8.
22. de Jong SC, Stehouwer CD, van den Berg M, et al. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 1997; 78:1332-7.
23. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995;90:244-8.
24. Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25: 176-81.
25. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
26. Rigby AS, Vail A. Statistical methods in epidemiology. II: A commonsense approach to sample size estimation. Disabil Rehabil 1998;20:405-10.
27. Loehrer FM, Haefeli WE, Angst CP, et al. Effect of methionine loading on 5-methyltetrahydrofolate, S-adenosylmethionine and S-adenosylhomocysteine in plasma of healthy humans. Clin Sci (Lond) 1996;91:79-86.
28. Leeming RJ, Pollock A, Melville LJ, et al. Measurement of 5-methyltetrahydrofolic acid in man by high-performance liquid chromatography. Metabolism 1990;39:902-4.
29. Short PE, Williams CE, Picken AM, et al. Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci 1982; 39:351-5.
30. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
31. Delvin EE, Rozen R, Merouani A, et al. Influence of methylene- tetrahydrofolate reductase genotype, age, vitamin B-12, and folate status on plasma homocysteine in children. Am J Clin Nutr 2000; 72:1469-73.
32. Bates CJ, Mansoor MA, Gregory J, et al. Correlates of plasma homocysteine, cysteine and cysteinyl-glycine in respondents in the British National Diet and Nutrition Survey of young people aged 4-18 years, and a comparison with the survey of people aged 65 years and over. Br J Nutr 2002;87:71-9.
33. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.